Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
metronidazole-DRF1
- Development stage
- Unknown
- Lead developer
- Cosette Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral, Intravenous, Topical, Intravaginal
01
Overview
**Metronidazole-DRF1** is a drug presentation or code name that suggests a formulation or developer-specific variant of metronidazole. Metronidazole is a nitroimidazole-class antibiotic and antiprotozoal agent used to treat infections caused by anaerobic bacteria and certain parasites, such as *Trichomonas vaginalis*, *Entamoeba histolytica*, and *Giardia lamblia*. It works by diffusing into susceptible organisms and, after reduction and activation, creates cytotoxic free radicals that interact with DNA, causing strand breakage, loss of DNA helical structure, and cell death[1][2][3][5][7]. Metronidazole is FDA-approved and widely used in clinical settings, but information specific to the "DRF1" variant, such as unique properties or indications, is not available in current sources.
- Brand names
- metronidazole-DRF1metronidazole-DRF-1metronidazole-DRF 1
- Other names
- metronidazole-DRF1metronidazole-DRF-1metronidazole-DRF 1
02
Targets
NeuraminidaseCellular proteins and sulfhydryl-containing biomolecules in anaerobic/protozoal organisms
Beyond the preview
Go deeper on metronidazole-DRF1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on metronidazole-DRF1.